

World Journal of *Clinical Cases*

World J Clin Cases 2022 July 26; 10(21): 7187-7619



Contents

Thrice Monthly Volume 10 Number 21 July 26, 2022

OPINION REVIEW

- 7187 Effects of glucocorticoids on leukocytes: Genomic and non-genomic mechanisms
Jia WY, Zhang JJ

MINIREVIEWS

- 7195 Apheresis: A cell-based therapeutic tool for the inflammatory bowel disease
Yasmin F, Najeeb H, Naeem U, Moeed A, Koritala T, Surani S
- 7209 *Helicobacter pylori* infection and small intestinal bacterial overgrowth—more than what meets the eye
Dharan M, Wozny D
- 7215 Anatomy of the anterolateral ligament of the knee joint
Park JG, Han SB, Rhim HC, Jeon OH, Jang KM

ORIGINAL ARTICLE

Clinical and Translational Research

- 7224 Molecular mechanisms of Biyu decoction as treatment for psoriasis: A network pharmacology and molecular docking study
Wang Z, Zhang HM, Guo YR, Li LL
- 7242 Expression of hepatocyte nuclear factor 4 alpha, wingless-related integration site, and β -catenin in clinical gastric cancer
Hu Q, Li LL, Peng Z, Yi P

Case Control Study

- 7256 Improved Pittsburgh Sleep Quality Index scores on first postoperative night achieved by propofol anesthesia in patients undergoing ambulatory gynecologic surgery
Hu CH, Chou WY
- 7265 Efficacy of Guhong injection *versus* Butylphthalide injection for mild ischemic stroke: A multicenter controlled study
Zhang WW, Xin J, Zhang GY, Zhai QJ, Zhang HM, Wu CS

Retrospective Study

- 7275 Clinical values of Barcelona Clinic Liver Cancer subgroup and up-to-7 criteria in intermediate stage hepatocellular carcinoma with transcatheter arterial chemoembolization
Lee SW, Peng YC, Lien HC, Ko CW, Tung CF, Chang CS
- 7285 Intervention effect of encouraging mental and programmed nursing of patients in interventional operating room on their compliance and bad moods
Chi RB, Cai YY, Mao HP

- 7293** Preoperative neoadjuvant chemotherapy in patients with breast cancer evaluated using strain ultrasonic elastography
Pan HY, Zhang Q, Wu WJ, Li X
- 7302** Risk factors for delayed intracranial hemorrhage secondary to ventriculoperitoneal shunt: A retrospective study
Chen JC, Duan SX, Xue ZB, Yang SY, Li Y, Lai RL, Tan DH
- 7314** Sequential treatment of severe pneumonia with respiratory failure and its influence on respiratory mechanical parameters and hemodynamics
Niu BY, Wang G, Li B, Zhen GS, Weng YB
- 7324** Effects of alendronate sodium combined with InterTan on osteoporotic femoral intertrochanteric fractures and fracture recurrence
Wang KM, Wei SP, Yin XY, Meng QJ, Kong YM
- 7333** Correlation of magnetic resonance imaging quantitative parameters and apparent diffusion coefficient value with pathological breast cancer
Wang Z, Ren GY, Yin Q, Wang Q
- 7341** Risk factors for delirium after surgery for craniocerebral injury in the neurosurgical intensive care unit
Chen RY, Zhong CH, Chen W, Lin M, Feng CF, Chen CN

Observational Study

- 7348** Effect of osteoarthritic knee flexion deformity correction by total knee arthroplasty on sagittal spinopelvic alignment in Indian population
Puthiyapura LK, Jain M, Tripathy SK, Puliappadamb HM
- 7356** Imaging characteristics of orbital peripheral nerve sheath tumors: Analysis of 34 cases
Dai M, Wang T, Wang JM, Fang LP, Zhao Y, Thakur A, Wang D

Randomized Controlled Trial

- 7365** Comparison of involved-field intensity-modulated radiotherapy combined with S-1 *vs* radiotherapy alone for elderly patients with esophageal cancer
Liu LH, Yan MH, Di YP, Fu ZG, Zhang XD, Li HQ

Randomized Clinical Trial

- 7376** Dexmedetomidine in pediatric unilateral internal inguinal ring ligation
Liu G, Zhang L, Wang HS, Lin Y, Jin HQ, Wang XD, Qiao WN, Zhang YT, Sun JQ, Liu ZN

META-ANALYSIS

- 7386** Impact of cancer on mortality rates in patients with sepsis: A meta-analysis and meta-regression of current studies
Xiang MJ, Chen GL

CASE REPORT

- 7397** Updated clinical and glycomic features of mannosyl-oligosaccharide glucosidase deficiency: Two case reports
Abuduxikuer K, Wang L, Zou L, Cao CY, Yu L, Guo HM, Liang XM, Wang JS, Chen L
- 7409** Solitary necrotic nodules of the liver with "ring"-like calcification: A case report
Bao JP, Tian H, Wang HC, Wang CC, Li B
- 7415** Corticosteroid-induced bradycardia in multiple sclerosis and maturity-onset diabetes of the young due to hepatocyte nuclear factor 4-alpha mutation: A case report
Sohn SY, Kim SY, Joo IS
- 7422** Essential thrombocythemia with non-ST-segment elevation myocardial infarction as the first manifestation: A case report
Wang ZM, Chen WH, Wu YM, Wang LQ, Ye FL, Yin RL
- 7429** Extranasopharyngeal angiofibroma in children: A case report
Yan YY, Lai C, Wu L, Fu Y
- 7438** Deep Sylvian fissure meningiomas: A case report
Wang A, Zhang X, Sun KK, Li C, Song ZM, Sun T, Wang F
- 7445** Acute pulmonary embolism originating from upper limb venous thrombosis following breast cancer surgery: Two case reports
Duan Y, Wang GL, Guo X, Yang LL, Tian FG
- 7451** Managing spondylitis tuberculosis in a patient with underlying diabetes and hypothyroidism: A case report
Novita BD, Muliono AC, Wijaya S, Theodora I, Tjahjono Y, Supit VD, Willianto VM
- 7459** Ovarian mucinous tumor with mural nodules of anaplastic carcinoma: Three case reports
Wang XJ, Wang CY, Xi YF, Bu P, Wang P
- 7467** Transcatheter arterial infusion chemotherapy and embolization for primary lacrimal sac squamous cell carcinoma: A case report
Sun MH, Yi WD, Shen L, Zhou L, Lu JX
- 7474** Programmed cell death-1 inhibitor combination treatment for recurrent proficient mismatch repair/microsatellite-stable type endometrial cancer: A case report
Zhai CY, Yin LX, Han WD
- 7483** Novel compound heterozygous mutation of *SLC12A3* in Gitelman syndrome co-existent with hyperthyroidism: A case report and literature review
Qin YZ, Liu YM, Wang Y, You C, Li LN, Zhou XY, Lv WM, Hong SH, Xiao LX
- 7495** Successful treatment of hyperglycemia with liraglutide in a hospitalized 27-year-old patient with schizophrenia: A case report
Zhang L, Yu WJ, Zhu H, Li HF, Qiao J

- 7502** Refractory lymphoma treated with chimeric antigen receptor T cells combined with programmed cell death-1 inhibitor: A case report
Zhang CJ, Zhang JY, Li LJ, Xu NW
- 7509** Median arcuate ligament syndrome with retroperitoneal haemorrhage: A case report
Lu XC, Pei JG, Xie GH, Li YY, Han HM
- 7517** Novel frameshift mutation in the *AHDC1* gene in a Chinese global developmental delay patient: A case report
Lin SZ, Xie HY, Qu YL, Gao W, Wang WQ, Li JY, Feng XC, Jin CQ
- 7523** Selective nerve block for the treatment of neuralgia in Kummell's disease: A case report
Zhang X, Li ZX, Yin LJ, Chen H
- 7531** Traditional Chinese medicine manipulative reduction combined with percutaneous vertebroplasty for treating type III Kummell's disease: A case report
Hao SS, Zhang RJ, Dong SL, Li HK, Liu S, Li RF, Ren HH, Zhang LY
- 7539** Differential diagnosis and treatment of foot drop caused by an extraneural ganglion cyst above the knee: A case report
Won KH, Kang EY
- 7545** Effect of hydrogen intervention on refractory wounds after radiotherapy: A case report
Zhao PX, Luo RL, Dang Z, Wang YB, Zhang XJ, Liu ZY, Wen XH, Liu MY, Zhang MZ, Adzavon YM, Ma XM
- 7553** Chronic urticaria associated with lung adenocarcinoma — a paraneoplastic manifestation: A case report and literature review
Jiménez LF, Castellón EA, Marengo JD, Mejía JM, Rojas CA, Jiménez FT, Coronell L, Osorio-Llanes E, Mendoza-Torres E
- 7565** Spinal giant cell-rich osteosarcoma-diagnostic dilemma and treatment strategy: A case report
Tseng CS, Wong CE, Huang CC, Hsu HH, Lee JS, Lee PH
- 7571** Primary clear cell sarcoma of soft tissue in the posterior cervical spine invading the medulla oblongata: A case report
Liu CC, Huang WP, Gao JB
- 7577** *Pseudomonas aeruginosa*-related effusive-constrictive pericarditis diagnosed with echocardiography: A case report
Chen JL, Mei DE, Yu CG, Zhao ZY
- 7585** Maternal peripartum bacteremia caused by intrauterine infection with *Comamonas kerstersii*: A case report
Qu H, Zhao YH, Zhu WM, Liu L, Zhu M
- 7592** Considerations of single-lung ventilation in neonatal thoracoscopic surgery with cardiac arrest caused by bilateral pneumothorax: A case report
Zhang X, Song HC, Wang KL, Ren YY

- 7599** Rare primary rectal mucosa-associated lymphoid tissue lymphoma with curative resection by endoscopic submucosal dissection: A case report and review of literature

Tao Y, Nan Q, Lei Z, Miao YL, Niu JK

- 7609** Differences in examination results of small anastomotic fistula after radical gastrectomy with afterward treatments: A case report

Lu CY, Liu YL, Liu KJ, Xu S, Yao HL, Li L, Guo ZS

LETTER TO THE EDITOR

- 7617** Baseline differences may impact on relationship between dietary tryptophan and risk of obesity and type 2 diabetes

Ren XH, Ye YW, He LP

ABOUT COVER

Editorial Board Member of *World Journal of Clinical Cases*, Rajesh Kumar Rajnish, MBBS, MS, Assistant Professor, Department of Orthopaedics, All India Institute of Medical Sciences, Bilaspur, Bilaspur 174001, Himachal Pradesh, India. duktiraj@gmail.com

AIMS AND SCOPE

The primary aim of *World Journal of Clinical Cases* (WJCC, *World J Clin Cases*) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

INDEXING/ABSTRACTING

The WJCC is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Current Contents®/Clinical Medicine, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 Edition of Journal Citation Reports® cites the 2021 impact factor (IF) for WJCC as 1.534; IF without journal self cites: 1.491; 5-year IF: 1.599; Journal Citation Indicator: 0.28; Ranking: 135 among 172 journals in medicine, general and internal; and Quartile category: Q4. The WJCC's CiteScore for 2021 is 1.2 and Scopus CiteScore rank 2021: General Medicine is 443/826.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: *Ying-Yi Yuan*; Production Department Director: *Xiang Li*; Editorial Office Director: *Jin-Lei Wang*.

NAME OF JOURNAL

World Journal of Clinical Cases

ISSN

ISSN 2307-8960 (online)

LAUNCH DATE

April 16, 2013

FREQUENCY

Thrice Monthly

EDITORS-IN-CHIEF

Bao-Gan Peng, Jerzy Tadeusz Chudek, George Kontogeorgos, Maurizio Serati, Ja Hyeon Ku

EDITORIAL BOARD MEMBERS

<https://www.wjnet.com/2307-8960/editorialboard.htm>

PUBLICATION DATE

July 26, 2022

COPYRIGHT

© 2022 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>

Essential thrombocythemia with non-ST-segment elevation myocardial infarction as the first manifestation: A case report

Zhi-Ming Wang, Wei-Hai Chen, Yan-Ming Wu, Lin-Quan Wang, Fu-Long Ye, Ren-Lin Yin

Specialty type: Anatomy and morphology

Provenance and peer review:

Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): 0
Grade C (Good): C, C, C
Grade D (Fair): 0
Grade E (Poor): 0

P-Reviewer: Barosi G, Italy; Gaman MA, Romania; Marickar F, India

Received: September 29, 2021

Peer-review started: September 29, 2021

First decision: November 11, 2021

Revised: November 24, 2021

Accepted: June 16, 2022

Article in press: June 16, 2022

Published online: July 26, 2022



Zhi-Ming Wang, Wei-Hai Chen, Yan-Ming Wu, Lin-Quan Wang, Fu-Long Ye, Ren-Lin Yin, Department of Cardiology, Suzhou Ninth People's Hospital, Soochow University, Suzhou 215200, Jiangsu Province, China

Corresponding author: Ren-Lin Yin, MD, Chief Doctor, Department of Cardiology, Suzhou Ninth People's Hospital, Soochow University, No. 2666 Ludang Road, Wujiang District, Suzhou 215000, Jiangsu Province, China. y13776080241@163.com

Abstract

BACKGROUND

We report a case of essential thrombocythemia (ET) in a 44-year-old male who exhibited non-ST-segment-elevation myocardial infarction (NSTEMI) as the first manifestation without known cardiovascular risk factors (CVRFs). For the first time, we reported a left main trifurcation lesion in NSTEMI caused by ET, including continuous stenosis lesions from the left main to the ostial left anterior descending (LAD) artery and an obvious thrombotic lesion in the ostial and proximal left circumflex (LCX) artery. There was 60% diffuse stenosis in the left main (LM) that extended to the ostial LAD, thrombosis of the ostial LAD and proximal LCX, and 90% stenosis in the proximal LCX. During the operation, thrombus aspiration was performed, but no obvious thrombus was aspirated. Performing the kissing balloon technique (KBT) in the LCX and LM unexpectedly increased the narrowness of the LAD. Then, the single-stent crossover technique, final kissing balloon technique and proximal optimization technique (POT) were performed. On the second day after percutaneous coronary intervention (PCI), the number of platelets (PLTs) still increased significantly to as high as $696 \times 10^9/L$. The bone marrow biopsy done later, together with JAK2 (exon 14) V617F mutation, confirms the diagnosis of ET. Hydroxyurea was administered to inhibit bone marrow proliferation to control the number of PLTs.

CASE SUMMARY

A 44-year-old male patient went to a local hospital for treatment for intermittent chest pain occurring over 8 h. The examination at the local hospital revealed elevated cTnI and significantly elevated platelet. Then, he was diagnosed with acute myocardial infarction and transferred to our hospital for emergency interventional treatment by ambulance. During the operation, thrombus aspiration, the single-stent crossover technique, final kissing balloon technique and POT were performed. Dual antiplatelet therapy comprising aspirin and ticagrelor was used after PCI. Evidence of mutated JAK2 V617F and bone marrow

biopsy shown the onset of ET. Together with JAK2 (exon 14) V617F mutation, ET was diagnosed according to the World Health Organization (WHO) diagnostic criteria, and the patient was placed on hydroxyurea. During the one-year postoperative period, repeated examinations showed a slight increase in PLTs, but the patient no longer had chest tightness, chest pain or bleeding or developed new thromboembolisms.

CONCLUSION

Routine physical examinations and screenings are conducive to the early detection of ET, and the risk for thrombosis should be assessed. Then, active antiplatelet therapy and myelosuppression therapy should be used for high-risk ET patients.

Key Words: Essential thrombocythemia; Non-ST-segment-elevation myocardial infarction; Percutaneous coronary intervention; Hydroxyurea; Case report

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: The emergency interventional treatment plan for acute myocardial infarction (AMI) caused by essential thrombocythemia is generally the same as that for AMI, and if conditions permit, intravenous ultrasound can provide imaging guidance for stent implantation. Taking aspirin to prevent the number of platelet (PLT) aggregation is very important, and conventional anticoagulation therapy is not recommended. For patients with significantly elevated PLT counts, achieving bone marrow suppression and control of PLT counts are also very important. The ideal target number of PLTs should be below 400×10^9 /L.

Citation: Wang ZM, Chen WH, Wu YM, Wang LQ, Ye FL, Yin RL. Essential thrombocythemia with non-ST-segment elevation myocardial infarction as the first manifestation: A case report. *World J Clin Cases* 2022; 10(21): 7422-7428

URL: <https://www.wjgnet.com/2307-8960/full/v10/i21/7422.htm>

DOI: <https://dx.doi.org/10.12998/wjcc.v10.i21.7422>

INTRODUCTION

Essential thrombocythemia is a group of relatively chronic myeloproliferative diseases. It is characterized by the abnormal proliferation of megakaryocytes in the bone marrow and a significant increase in peripheral blood platelet counts. The main clinical manifestations are increased incidence of thromboembolic and bleeding events[1]. Research shows that thrombotic complications are the main factors affecting mortality in essential thrombocythemia (ET) patients[2], and the incidence of major haemorrhagic complications was very low in comparison with that of thrombotic episodes. These complications are most common in cases of ischaemia caused by arterial thrombosis, followed by venous thrombosis and microcirculation disorders[3]. Early recognition of ET and the International Prognostic Score for Essential Thrombocythemia (IPSET) can be used as some of the most important methods to prevent and treat thrombotic events caused by ET[4].

CASE PRESENTATION

Chief complaints

Chest pain for 8 h.

History of present illness

A 44-year-old male patient was admitted to our hospital with complaints of intermittent chest pain for 9 h. Starting at 11:45 am on June 21, 2021, chest pain and sweating appeared in a resting state with no obvious inducement and was located in the middle and lower part of the sternum, spreading to the shoulder and back. The whole process lasted for more than 10 minutes, and the chest pain was relieved by rest; however, during this period, the chest pain recurred intermittently. Later, he went to a local hospital for treatment. Electrocardiogram (ECG) revealed sinus rhythm, horizontal ST segment elevation of 0.05 mV in lead aVR, upsloping ST segment depression of 0.1-0.25 mV in leads V1-V4, and a cTnI of 2.44 ng/mL, so he was diagnosed with acute myocardial infarction(AMI). Then, he was

transferred to our hospital for emergency interventional treatment by 120 first aid.

History of past illness

The patient had no history of hypertension, diabetes, or hyperlipidaemia. However, he had a history of thrombocytosis, without a systematic diagnosis or previous treatment.

Personal and family history

He denied any relevant personal medical history or a family history.

Physical examination

The physical examination revealed a patient in pain with clear consciousness, coarse breath sounds in both lungs, no rales. His heart rate (HR) of 88 times/min with no obvious murmur. The blood pressure (BP) was 140/98 mmHg. The abdomen was soft, with no tenderness and no rebound pain.

Laboratory examinations

His initial peripheral blood panel findings were as follows: cTnI, 2.44 ng/mL; PLT, $736 \times 10^9/L$; and normal white blood cell (WBC) count, haemoglobin (Hb), D-dimer, prothrombin and partial thromboplastin time.

Imaging examinations

ECG revealed sinus rhythm, horizontal ST segment elevation of 0.05 mV in lead avR, and upsloping ST segment depression of 0.1-0.25 mV in leads V1-V4 (Figure 1).


FINAL DIAGNOSIS

The final diagnosis in the presented case was non-ST-segment-elevation myocardial infarction and ET.

TREATMENT


Emergency coronary angiography (CAG) was performed *via* a right radial artery approach and showed a left main (LM) bifurcation lesion with a Medina classification of 1%, 0%, 1%, 60% diffuse stenosis in the LM that extended to the ostial left anterior descending (LAD), 30% stenosis in the ostial LAD, thrombosis of the ostial LAD and proximal left circumflex (LCX), and 90% stenosis in the proximal LCX. The proximal LCX branched into a larger first obtuse marginal (OM1) artery, with a slow blood flow speed in OM1 and thrombolysis in myocardial infarction (TIMI) flow grade of 2. There was no obvious stenosis of the right coronary artery (Figure 2).

The process of interventional therapy could be described was not straightforward. After engaging the LM artery with a 6-Fr extra backup (EBU) 3.5 guide catheter (Launcher; Medtronic, United States), we advanced two guide wires (Runthrough NS, Terumo, Tokyo, Japan) to the distal LAD and LCX. After predilatation of the proximal LCX using a 2.0 mm $\times$ 20 mm semi-compliant balloon (Sprinter Legend, Medtronic, United States), the thrombus load of the ostial LCX was still very heavy. Tirofiban (10 mL) was injected twice through the guide catheter to try to reduce the thrombus load but did not achieve the expected results. Then, intracoronary thrombus aspiration was conducted in the LCX and LAD, but no thrombus was extracted. We performed balloon dilation again; this time choosing 2 new 2.5 mm $\times$ 20 mm semi-compliant balloons (Sprinter Legend, Medtronic, United States) to perform the KBT in the LCX and LM. Repeat angiography revealed that the proximal LAD stenosis significantly increased to 70% to 80%, probably from plaque displacement resulting in an increase in the stenosis of the ostial and proximal LAD. At the same time, the previously relieved chest pain worsened again. Considering continuous stenosis lesions from the LM to the ostial LAD and an obvious thrombotic lesion in the ostial LCX, we adjusted the initial treatment strategy to a revascularization strategy from the LAD to the unprotected LM using the single-stent crossover technique[5] to avoid the implantation of more stents and reduce the risk of acute stent thrombosis in the area of the stent. Ostial LM/LAD crossover stent implantation was conducted with a 3.75 mm $\times$ 24 mm drug-eluting stent (DES) (Endeavor Resolute, Medtronic, United States) at 12 atm. Repeat CAG showed no residual stenosis in the LAD and a TIMI grade of 3, but the ostial LCX was affected. Then, we rewired another guide wire that passed through the stent mesh to the LCX and used a 1.5 mm $\times$ 15 mm semi-compliant balloon (Sprinter Legend, Medtronic, United States) to fully predilate the stent mesh. Then, 3.75 mm $\times$ 15 mm and 3.5 mm $\times$ 15 mm non-compliant balloons (NC Sprinter, Medtronic, United States) were placed at the LM and ostial LCX, respectively, followed by the final kissing balloon technique. Finally, the LM proximal optimization technique (POT) was performed. Repeat angiography showed 60% residual stenosis in the proximal LCX and a TIMI flow grade of 3 (Figure 2).



DOI: 10.12998/wjcc.v10.i21.7422 Copyright ©The Author(s) 2022.

Figure 1 Preoperative and postoperative electrocardiograms.



DOI: 10.12998/wjcc.v10.i21.7422 Copyright ©The Author(s) 2022.


Figure 2 Coronary angiography and percutaneous coronary intervention. A: There was no obvious stenosis in the right coronary artery; B and C: Left main (LM) bifurcation lesion with a Medina classification of 1%, 0%, 1%, 60% diffuse stenosis in the LM that extended to the ostial left anterior descending (LAD), 30% stenosis in the ostial LAD, thrombosis of the ostial LAD and proximal left circumflex (LCX), 90% stenosis in the proximal LCX, and coronary slow flow in the obtuse marginal (OM); D: Final kissing balloon technique was performed; E and F: Finally, LM showed great expansion after stent treatment, and the thrombus load was significantly decreased in the ostial and proximal LCX. There was 60% residual stenosis in the ostial LCX, with a thrombolysis in myocardial infarction flow grade of 3 in the OM. The ostial LAD showed great expansion after stent treatment.

After percutaneous coronary intervention, triple antiplatelet therapy (with aspirin, ticagrelor and tirofiban) was given, an intravenous drip infusion of tirofiban was administered for 48 h (4 mL/h), followed by subcutaneous enoxaparin for 7 d (1 mg/kg every 12 h). On the second day, blood testing showed that the PLT count still increased significantly to as high as $696 \times 10^9/L$. The subsequent bone marrow biopsy showed that bone marrow hyperplasia was significantly active, the granulocyte/nucleated red blood cell ratio was normal, and megakaryocytes were common. With positive JAK-2 V617F mutation (Figure 3), ET was diagnosed. Finally, we used hydroxyurea to inhibit bone marrow

Genetic testing

Test items	JAK2 exon 12	JAK2 exon 12	CALR exon 9	MPL exon 10	CSF3R exon 14
Test results	Negative	Positive (+)	Negative	Negative	Negative

Bone marrow biopsy



DOI: 10.12998/wjcc.v10.i21.7422 Copyright ©The Author(s) 2022.

Figure 3 Genetic testing showed that the presence of a JAK2 (exon 14) V617F mutation. The bone marrow biopsy showed that bone marrow hyperplasia was significantly active, the granulocyte/nucleated red blood cell ratio was normal, and megakaryocytes were common.

proliferation to control the number of the number of platelets.

OUTCOME AND FOLLOW-UP

After percutaneous coronary intervention (PCI), the patient's chest pain improved significantly, and ECG showed that the ST segment, which had been elevated in lead avR and depressed in leads V1-V4, was restored to the equipotential line. Echocardiography showed that the patient's ejection fraction was 64%. There was no chest pain and no signs of bleeding after PCI. During the recent telephone follow-up (November 12, 2021), we learned that the patient's platelet count increased again after stopped taking hydroxyurea. At present, the patient takes medication regularly, including aspirin and hydroxyurea.

DISCUSSION

ET is a myeloproliferative neoplasm (MPN) that mainly manifests as a PLT count $\geq 450 \times 10^9/L$, the abnormal proliferation of megakaryocytes in the bone marrow, with the presence of JAK2, CALR or MPL driver mutations, and other causes of thrombocytosis excluded[6]. The annual incidence is 0.2 to 2.5 cases/100000, and the incidence varies from 0.2 to 2.5:100000 people per year, with a prevalence of 38 to 57 cases per 100000 people[7]. The main complications of ET are thromboembolism and a small number of bleeding events; a history of thrombosis, age > 60 years, and JAK2/MPL mutations are considered the three major risk factors for thrombosis[1,8,9]. Thromboembolic events in important target organs are usually fatal; therefore, early discovery, risk stratification to predict thrombosis and early treatment are very important for ET[4].

By searching PubMed, we found that AMI due to ET is infrequent, with fewer than 35 case reports published in the literature. There were significantly more thrombotic events in the left coronary artery than in the right coronary artery, but these events happen in the LCX rarely. In our study, for the first time, we reported a case of an LM trifurcation lesion in NSTEMI caused by ET, including continuous stenosis lesions from the LM to the ostial LAD and an obvious thrombotic lesion in the ostial and proximal LCX. For the trifurcation lesion in this case, the LAD stenosis was especially aggravated after predilation, and obvious thrombosis was observed in the LCX. An acutely increased thrombus load, acute stent occlusion and no reflow risk can be caused by implantation of a DES in the LCX, especially when double stents (DK-Crush, DK-Culotte, TAP) are used. The single-stent crossover technique was performed to reduce the risk of no reflow and in-stent restenosis and which seemed to be a favourable

option. In addition, for suitable lesions, a bioabsorbable stent is a relatively good choice, which can significantly shorten the time of antiplatelet therapy and reduce the risk of bleeding while avoiding long-term restenosis of the DES.

Intracoronary injections of tirofiban can improve thrombus load[10-13]; if there are no significant obstructive atherosclerotic plaques after the thrombus is aspirated and the TIMI flow grade is 3, it can be considered that there is no need to implant a DES in the emergency period. Usually, these AMI patients may be younger patients with no or low cardiovascular risk factors[14]. AMI caused by ET usually has a heavy thrombus load. Therefore, all operations during thrombus aspiration must be standardized. A sufficient negative pressure must be maintained in the aspiration catheter to actively prevent the thrombus from dislodging into other coronary arteries or peripheral blood vessels. Finally, low-dose aspirin to prevent platelet aggregation and the use of hydroxyurea can effectively reduce the occurrence of new and recurring vascular embolisms caused by ET.

CONCLUSION

Even if acute myocardial infarction is caused by ET, emergency interventional treatment is still necessary and should be carried out as soon as possible. Thrombus aspiration can be routinely applied, and platelet glycoprotein GPIIb/IIIa complexes (GPIIb/IIIa) can be routinely used in the coronary arteries. If the coronary flow is still unsatisfactory after thrombus aspiration, stent placement is needed and an important guarantee for establishing early revascularization and preventing restenosis in the short term. Achieving and maintain a TIMI flow grade of 3 is the purpose of the operation. Intravascular ultrasound (IVUS) can be used to distinguish between a simple thrombus or a plaque rupture and then provide imaging guidance for stent implantation. The fewest stents as possible should be implanted, and absorbable stents may be the first choice for patients with no known CVRFs. Routine physical examinations and screenings are conducive to the early detection of ET, and the risk of thrombosis should be assessed. Liquid biopsy may play a greater role in the future[15]. Then, patients with high-risk ET should be given active antiplatelet therapy (aspirin) and myelosuppressive therapy (hydroxyurea).

FOOTNOTES

Author contributions: Wang ZM and Yin RL contributed to the conceptualization of the study; Wang LQ and Ye FL contributed to the methodology; Chen WH and Wu YM contributed to the formal analysis and data curation; Wang ZM contributed to the writing-original draft preparation; Yin RL provided supervision; all authors have read and agreed to the published version of the manuscript.

Informed consent statement: Study participant provided informed written consent prior to study enrollment.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: China

ORCID number: Zhi-Ming Wang 0000-0001-9362-0900; Wei-Hai Chen 0000-0001-6622-4558; Yan-Ming Wu 0000-0002-3064-5091; Lin-Quan Wang 0000-0001-5883-1307; Fu-Long Ye 0000-0003-1936-7147; Ren-Lin Yin 0000-0001-8879-9862.

S-Editor: Xing YX

L-Editor: A

P-Editor: Xing YX

REFERENCES

- 1 Tefferi A, Pardanani A. Essential Thrombocythemia. *N Engl J Med* 2019; **381**: 2135-2144 [PMID: 31774958 DOI: 10.1056/NEJMcp1816082]

- 2 **Maleknia M**, Shahrabi S, Ghanavat M, Vosoughi T, Saki N. Essential thrombocythemia: a hemostatic view of thrombogenic risk factors and prognosis. *Mol Biol Rep* 2020; **47**: 4767-4778 [PMID: [32472297](#) DOI: [10.1007/s11033-020-05536-x](#)]
- 3 **Bellucci S**. [Vascular complications of essential thrombocythemia]. *Bull Acad Natl Med* 2007; **191**: 519-30; discussion 530 [PMID: [18072651](#)]
- 4 **Mora B**, Passamonti F. Developments in diagnosis and treatment of essential thrombocythemia. *Expert Rev Hematol* 2019; **12**: 159-171 [PMID: [30793984](#) DOI: [10.1080/17474086.2019.1585239](#)]
- 5 **Neumann FJ**, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Jüni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO; ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. *Eur Heart J* 2019; **40**: 87-165 [PMID: [30165437](#) DOI: [10.1093/eurheartj/ehy394](#)]
- 6 **Barbui T**, Thiele J, Gisslinger H, Finazzi G, Vannucchi AM, Tefferi A. The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances. *Blood Rev* 2016; **30**: 453-459 [PMID: [27341755](#) DOI: [10.1016/j.blre.2016.06.001](#)]
- 7 **Accurso V**, Santoro M, Mancuso S, Napolitano M, Siragusa S. The Essential Thrombocythemia in 2020: What We Know and Where We Still Have to Dig Deep. 2020
- 8 **Tefferi A**, Vannucchi AM, Barbui T. Essential thrombocythemia treatment algorithm 2018. *Blood Cancer J* 2018; **8**: 2 [PMID: [29321520](#) DOI: [10.1038/s41408-017-0041-8](#)]
- 9 **Carobbio A**, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Vannucchi AM, Antonioli E, Gisslinger H, Buxhofer-Ausch V, Finazzi G, Gangat N, Tefferi A, Barbui T. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. *Blood* 2011; **117**: 5857-5859 [PMID: [21490340](#) DOI: [10.1182/blood-2011-02-339002](#)]
- 10 **Gül C**, Kürüm T, Demir M, Ozbay G, Vural O, Iqbal O, Fareed J. Acute myocardial infarction in a patient with essential thrombocythemia treated with glycoprotein IIb/IIIa inhibitor. *Clin Appl Thromb Hemost* 2004; **10**: 77-79 [PMID: [14979411](#) DOI: [10.1177/107602960401000114](#)]
- 11 **Alioglu E**, Tuzun N, Sahin F, Kosova B, Saygi S, Tengiz I, Turk U, Ozsan N, Ercan E. Non ST-segment elevation myocardial infarction in patient with essential thrombocythemia. *Thromb J* 2009; **7**: 1 [PMID: [19232081](#) DOI: [10.1186/1477-9560-7-1](#)]
- 12 **Bildirici U**, Celikyurt U, Ural E. Essential thrombocythemia: a case of acute ST-segment elevation myocardial infarction in a young female. *Clin Cardiol* 2009; **32**: 104-105 [PMID: [19215011](#) DOI: [10.1002/clc.20426](#)]
- 13 **Zhang Z**, Wan X, Liu Y, Lin X, Ni Z, Yang X, Zhang L. Non-ST-segment elevation myocardial infarction in a patient with essential thrombocythemia treated with glycoprotein IIb/IIIa inhibitor: a case report. *Clin Appl Thromb Hemost* 2011; **17**: 532-534 [PMID: [20724303](#) DOI: [10.1177/1076029610379846](#)]
- 14 **Niccoli G**, Scalone G, Crea F. Acute myocardial infarction with no obstructive coronary atherosclerosis: mechanisms and management. *Eur Heart J* 2015; **36**: 475-481 [PMID: [25526726](#) DOI: [10.1093/eurheartj/ehu469](#)]
- 15 **Găman MA**, Cozma MA, Dobrică EC, Crețoiu SM, Găman AM, Diaconu CC. Liquid Biopsy and Potential Liquid Biopsy-Based Biomarkers in Philadelphia-Negative Classical Myeloproliferative Neoplasms: A Systematic Review. *Life (Basel)* 2021; **11** [PMID: [34357048](#) DOI: [10.3390/Life11070677](#)]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

